Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Century Therapeutics (IPSC – Research Report) ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), currently valued at $1.9 billion and trading near its 52-week low, announced the results of its 2025 Annual Meeting of Stockholders, which took place ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), currently valued at $1.9 billion and trading near its 52-week low, announced the results of its 2025 Annual Meeting of Stockholders, which took place on ...

In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

a condition with no approved therapies and a lengthy list of failed drug candidates – via a deal with Arrowhead Pharmaceuticals. The bolt-on deal comes – which includes an upfront payment of $ ...